Search PubMed⌕ Search

Biomedical subjects

T T Oei

Publications and source records attributed to T T Oei.

8 recordsLinked to original sources

Mitogen-activated protein kinase in neutrophils and enucleate neutrophil cytoplasts: evidence for regulation of cell-cell adhesion.

We employed neutrophils and enucleate neutrophil cytoplasts to study the activation of the mitogen-activated protein kinases (MAPKs) p44erk1 and p42erk2 in neutrophils by inflammatory agonists that engage G protein-linked receptors. Formyl-methionyl-leucyl-phenylalanine (FMLP) rapidly and transiently activated MAPK in neutrophils and cytoplasts, consistent with a role in signaling for neutrophil functions. FMLP stimulated p2lras activation in neutrophils and Raf-1 translocation from cytosol to plasma membrane in cytoplasts, with kinetics consistent with events upstream of MAPK activation. Insulin, a protein tyrosine kinase receptor (PTKR) agonist, stimulated neutrophil MAPK activation, demonstrating an intact system of PTKR signaling in these post-mitotic cells. FMLP- and insulin-stimulated MAPK activation in cytoplasts were inhibited by Bt2cAMP, consistent with signaling through Raf-1 and suggesting a mechanism for cAMP inhibition of neutrophil function. However, Bt2cAMP had no effect on FMLP-stimulated MAPK activation in neutrophils. The extent of MAPK activation by various chemoattractants correlated with their capacity to stimulate neutrophil and cytoplast homotypic aggregation. Consistent with its effects on MAPK, Bt2cAMP inhibited FMLP-stimulated aggregation in cytoplasts but not neutrophils. Insulin had no independent effect but primed neutrophils for aggregation in response to FMLP. Our studies support a p2lras-, Raf-1-dependent pathway for MAPK activation in neutrophils and suggest that neutrophil adhesion may be regulated, in part, by MAPK.

Calcium-Calmodulin-Dependent Protein Kinases↗

A decade of psychiatric consultation with elderly patients in a Dutch general hospital.

A retrospective case study of ten years of psychiatric consultation with elderly in a Dutch general hospital is presented. The number of psychiatric consultations is increasing more than would be expected from admission rates or demographic changes. Of these, 25.4% were diagnosed as suffering from mood disorder and 34.1% from organic mental disorder. Somatic and psychiatric diagnoses alone seem inadequate to describe the severe problems of this specific group of patients.

Aged↗

Kinetics of carbamazepine and carbamazepine-epoxide, determined by use of plasma and saliva.

The concentration-time curves of carbamazepine (CBZ) and its metabolite (carbamazepine-10,11-epoxide; CBZ-epoxide) were determined in patients undergoing long-term antiepileptic drug treatment with the use of plasma and saliva data. Plasma and saliva samples were assayed concurrently for each patient by liquid chromatography. There was excellent linear correlation between CBZ levels in saliva and plasma (r = 0.991, p less than 0.001) over a large concentration range. The saliva/plasma ratio for CBZ concentration was 0.26 +/- 0.01 (SD). Since CBZ binding to plasma proteins is in the order of 76%, saliva CBZ concentration seems to reflect the unbound fraction of the drug in plasma. CBZ-epoxide has not been detected in saliva. The pharmacokinetic parameters of CBZ-epoxide were determined in 6 patients. The pharmacokinetic parameters of CBZ obtained from saliva concentrations were in excellent agreement with those obtained from plasma concentrations. Thus, CBZ determination in saliva is convenient for controlling blood levels in patients as well as for studying pharmacokinetics. The half-life, the relative body clearance of CBZ, and the metabolite concentration during steady-state, expressed as percent the parent compound, appear to be significantly different in patients on single and combined drug therapy.

Adolescent↗

Relationship between carbamazepine concentrations in plasma and saliva in man as determined by liquid chromatography.

The concentration of carbamazepine in plasma and saliva was determined in 7 subjects receiving carbamazepine. Plasma and saliva samples were assayed was an excellent linear relationship between carbamazepine concentrations in saliva and plasma (r = 0.991, p less than 0.001) over a plasma concentration range of 0.2--8.0 microgram/ml. The saliva/plasma ratio for carbamazepine was 0.26 +/- 0.02 (S.D.). Since carbamazepine binding to plasma proteins is in the order of 75%, the saliva concentration seems to reflect the concentration of the free drug in plasma. There is very little intrasubject and intersubject variation in the concentration ratio of carbamazepine. This study demonstrates that carbamazepine determination in saliva is a convenient method for optimizing blood levels of patients as well as for the study of pharmacokinetic properties.

Carbamazepine↗

Safety and efficacy of prolonged treatment with Tremblex (dexetimide), an antiparkinsonian agent. A controlled study.

The trial involved 69 female, long-stay inpatients of the Voorburg mental hospital, of a median age of 50 years. Two groups were formed at the start of the trial. The first group (51 patients) on a maintenance therapy with orphenadrine, were now put on oral dexetimide. Individually adapted dosages ranged from 0.5 to 1.5 mg daily. The control group (18 patients) of antiparkinsonian agents did not take any in the course of the study either. After three and six months (end of trial) biochemical and haematologic parameters were assessed. Clinical evaluation of extrapyramidal symptoms was made in the dexetimide group. All patients of the control group and 47 of the dexetimide group completed the trial. Both groups were shown to be comparable with regard to all parameters. Statistical analysis showed significant improvement in dexetimide-patients with regard to gross motor tremor, facial inexpressiveness, parkinsonian gait (after two weeks) + dyskinesia (after six months).

Adult↗